MUMBAI (Reuters) - India's Strides Arcolab and Eli Lilly will jointly manufacture and distribute generic cancer drugs for developing markets, the drugmakers said on Wednesday, as the U.S. company looks to expand its presence in emerging markets. The tie-up is the latest in a line of agreements between 'Big Pharma' companies eyeing greater access to high-growth emerging markets, and Indian companies looking for global expertise. Under the agreement, Strides subsidiary Agila Specialties will manufacture the generic oral and injectable cancer drugs that Lilly will register and market. ...
Read the full article...
(From Yahoo Diseases)